SCHEMBL29944843

SCHEMBL29944843

CCN(CC)CCc1c(C)c2ccc(OC)cc2oc1=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.55
ALDH1A1 P00352 7/20 0.55
HPGD P15428 6/20 0.55
HSD17B10 Q99714 5/20 0.55
GAA P10253 2/20 0.55
TP53 P04637 1/20 0.54
RAB9A P51151 5/20 0.54
NPC1 O15118 4/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
MAPT P10636 4/20 0.53
THRB P10828 1/20 0.53
NQO1 P15559 1/20 0.53
STS P08842 1/20 0.53
HSD17B3 P37058 1/20 0.50
POLB P06746 1/20 0.50
STAT1 P42224 1/20 0.50
ACHE P22303 2/20 0.49
BCHE P06276 1/20 0.49
TSHR P16473 1/20 0.49
MAOB P27338 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7141692 1.00 KDM4E (0.55) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL7141330 0.84 CYP2C9 (0.64) KDM4EALDH1A1HPGDHSD17B10GAA
Chromonar SCHEMBL309094 0.82 KDM4E (0.67) KDM4EALDH1A1HPGDHSD17B10GAA
Chromonar SCHEMBL29724124 0.82 KDM4E (0.67) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL1476174 0.82 HSD17B3 (0.74) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL29699265 0.82 KDM4E (0.60) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL18766190 0.82 KDM4E (0.60) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL8745753 0.82 NQO1 (0.61) KDM4EALDH1A1HPGDHSD17B10GAA
Chromonar SCHEMBL29351852 0.82 KDM4E (0.66) KDM4EALDH1A1HPGDHSD17B10GAA
Chromonar SCHEMBL122836 0.82 KDM4E (0.66) KDM4EALDH1A1HPGDHSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282764-A1 IMIDAZOLE HETEROCYCLE BASED COMPOUNDS AND METHODS OF TREATING CANCER KING ABDULAZIZ UNIVERSITY (SA) 2025-09-11 US disclosed
US-11479536-B1 Arylacetamides as AMP-activated protein kinase inhibitors and their use for treatment of breast cancer KING ABDULAZIZ UNIVERSITY (SA) 2022-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282764-A1 IMIDAZOLE HETEROCYCLE BASED COMPOUNDS AND METHODS OF TREATING CANCER H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TTBK2, CDK13 KDM4E 2443/4885ALDH1A1 1214/4885HPGD 1335/4885
US-11479536-B1 Arylacetamides as AMP-activated protein kinase inhibitors and their use for treatment of breast cancer PRKAA2, PRKAA1, PRKAG2 KDM4E 1837/4885ALDH1A1 1494/4885HPGD 1956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.